1-7 of 7
Sujan Kabir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Lindsay A.M. Rein, Firas El Chaer, Junichiro Yuda, Kazuya Shimoda, Raajit Rampal, Joseph M. Scandura, Akiyoshi Takami, James McCloskey, Michiko Ichii, Shuichi Shirane, Alessandra Iurlo, Prithviraj Bose, Alessandro Lucchesi, Giulia Benevolo, Idoroenyi Amanam, Pankit Vachhani, Srinivas K Tantravahi, Marcello Rotta, Yasushi Onishi, Jean-Jacques Kiladjian, Ciro Rinaldi, Nikki Granacher, Terrence Bradley, Anand Ashwin Patel, Michael Loschi, Samah Alimam, Stanley Cheung, Vincent Ribrag, Sujan Kabir, Masataka Seki, Karen Ansaldo, Guia Guffanti, Jinny Lee, Steven L. Warner, Jason M. Foulks, Ruben Mesa
Journal: Blood
Blood (2024) 144 (Supplement 1): 3179.
https://doi.org/10.1182/blood-2024-200999
Published: 2024
Journal Articles

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Firas El Chaer, Lindsay A.M. Rein, Junichiro Yuda, Kazuya Shimoda, Akiyoshi Takami, Michiko Ichii, James McCloskey, Joseph M. Scandura, Alessandra Iurlo, Prithviraj Bose, Tamanna Haque, Alessandro Lucchesi, Shuichi Shirane, Giulia Benevolo, Idoroenyi Amanam, Jean-Jacques Kiladjian, Pankit Vachhani, Srinivas K Tantravahi, Yasushi Onishi, Ciro Rinaldi, Marcello Rotta, Nikki Granacher, Anand Ashwin Patel, Michael Loschi, Samah Alimam, Terrence Bradley, Stanley Cheung, Vincent Ribrag, Sujan Kabir, Karen Ansaldo, Masataka Seki, Vincent Loksa, Zhonggai Li, Jason M. Foulks, Jatin Shah, Raajit Rampal
Journal: Blood
Blood (2024) 144 (Supplement 1): 655.
https://doi.org/10.1182/blood-2024-200312
Published: 2024
Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

John O. Mascarenhas, Raajit Rampal, Firas El Chaer, Vikas Gupta, Kazuya Shimoda, Jean-Jacques Kiladjian, Francesco Passamonti, Prithviraj Bose, Joseph M. Scandura, Ruben Mesa, Lindsay A.M. Rein, Junichiro Yuda, David M Ross, Timothy Devos, Moshe Talpaz, Ronald Hoffman, Sujan Kabir, Zhonggai Li, Jason M. Foulks, Karen Ansaldo, Masataka Seki, Vishnu Peddagali, Jatin Shah, Claire Harrison
Journal: Blood
Blood (2024) 144 (Supplement 1): 6629.
https://doi.org/10.1182/blood-2024-200268
Published: 2024
Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Lindsay A.M Rein, Firas El Chaer, Junichiro Yuda, Kazuya Shimoda, James McCloskey, Akiyoshi Takami, Tamanna Haque, Michiko Ichii, Shuichi Shirane, Masafumi Fukaya, Joseph M. Scandura, Terrence Bradley, Pankit Vachhani, Takayuki Tabayashi, Steven Green, Stanley Cheung, Prithviraj Bose, Sharad Khurana, Casey L. O'Connell, Idoroenyi Amanam, David M. Ross, Sujan Kabir, Masataka Seki, Mark Wade, Vishnu Peddagali, Zhonggai Li, Jatin Shah, Raajit K. Rampal
Journal: Blood
Blood (2023) 142 (Supplement 1): 626.
https://doi.org/10.1182/blood-2023-180164
Published: 2023
Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal
Journal: Blood
Blood (2022) 140 (Supplement 1): 594–595.
https://doi.org/10.1182/blood-2022-159086
Published: 2022
Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 670.
https://doi.org/10.1182/blood-2019-127119
Published: 2019
Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 4164.
https://doi.org/10.1182/blood-2019-128211
Published: 2019